NCT06067425
Source recordAI-normalized
A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia
This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.
AI analysis
Indication: Osteochondrodysplasia
Modality: small molecule
Target: SAR442501
Sponsor: Sanofi
Source URL: ClinicalTrials.gov
Source updated: Feb 25, 2025
Ingested: Jun 20, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SAR442501
View original source fields
Condition raw: Osteochondrodysplasia
Condition normalized: Osteochondrodysplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: SAR442501
Target normalized: SAR442501